Company Filing History:
3 out of 106 
1 out of 106 
Years Active: 2018-2022
Title: Kevin Flanigan: Innovator in Genetic Therapies
Introduction
Kevin Flanigan is a prominent inventor based in Columbus, OH (US), known for his significant contributions to the field of genetic therapies. He holds three patents that focus on innovative methods for treating muscular dystrophies, particularly Duchenne Muscular Dystrophy.
Latest Patents
One of his latest patents is titled "Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs." This invention relates to the use of recombinant adeno-associated virus (rAAV) for delivering polynucleotides aimed at treating Duchenne Muscular Dystrophy caused by the duplication of DMD exon 2. The invention provides rAAV products and methods for utilizing rAAV in the treatment of this condition. Another notable patent is "Methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene." This invention focuses on delivering oligomers to treat patients with a 5' mutation in their DMD gene, excluding exon 2 duplication. It offers methods and materials for activating an internal ribosome entry site in exon 5, leading to the translation of a functional truncated isoform of dystrophin. These methods can be applied to treat muscular dystrophies resulting from 5' mutations in the DMD gene, including Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.
Career Highlights
Kevin Flanigan has worked at notable institutions such as the Research Institute at Nationwide Children's Hospital and The University of Western Australia. His work has significantly advanced the understanding and treatment of genetic disorders.
Collaborations
He has collaborated with esteemed colleagues, including Nicolas Wein and Adeline Vulin-Chaffiol, contributing to the development of innovative therapeutic approaches.
Conclusion
Kevin Flanigan's work in genetic therapies exemplifies the impact of innovation in medicine. His patents and collaborations continue to pave the way for advancements in the treatment of muscular dystrophies.